Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pts) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II clinical trial.
Mustafa Khasraw
Research Funding - Merck Serono
Sally Anne McCowatt
No relevant relationships to disclose
Marc E. Buyse
No relevant relationships to disclose
Zoltan Kerstes
No relevant relationships to disclose
Michael Back
Consultant or Advisory Role - Merck Sharp & Dohme
Ganessan Kichenadasse
No relevant relationships to disclose
Helen Wheeler
Research Funding - Merck Serono